
There is a slight chance of reintervention within 2 years after the procedure among men who underwent artificial urinary sphincter (AUS) implantation for stress urinary incontinence (SUI) due to prostate cancer or benign prostatic hyperplasia (BPH) treatment, suggests a study.
Overall, 8,475 men (median age 69 years) in France were included in this population-based retrospective cohort study. Participants underwent a first-ever AUS implantation for male SUI after prostate cancer or BPH treatment between 1 January 2006 and 31 December 2018.
Reintervention-free survival rates (replacements and removals), estimated using the Kaplan-Meier method, was the primary outcome, while replacement and removal were secondary. The authors used a multivariable Cox proportional hazards model to explore the associations between patient and hospital factors and the risk of reintervention.
The reintervention-free survival rates were 71 percent (95 percent confidence interval [CI], 70‒72) at 2 years, 57 percent (95 percent CI, 55‒58) at 5 years, and 40 percent (95 percent CI, 38‒41) at 10 years. Moreover, the rates of removal-free survival were 83 percent (95 percent CI, 83‒84) at 2 years, 75 percent (95 percent CI, 74‒76) at 5 years, and 66 percent (95 percent CI, 65‒68) at 10 years.
In summary, the chance of reintervention within 2 years postimplantation was 29 percent, and the median time to reintervention was 6.6 years. At 10 years, the rate of reinternvention-free survival stood at 40 percent.
“These insights can inform therapeutic decision-making for patients and surgeons during the management of male SUI,” the authors said.